MAO-B INHIBITORS AND NASAL DECONGESTANTS
An isolated report describes a hypertensive crisis, which was attributed to an interaction between selegiline, ephedrine, and maprotiline. Rasagiline is expected to interact like selegiline.
In general, if selegiline is used at recommended doses it is selective for MAO-B and no restrictions are required. Nevertheless, this report suggests that, rarely, interactions are still possible, and some consider that patients taking selegiline should try to avoid pseudoephedrine. The manufacturers of rasagiline recommend against concurrent use of nasal decongestants that are indirectly-acting sym- pathomimetics, such as ephedrine and pseudoephedrine, due to the risk of hypertensive crises.
In general, if selegiline is used at recommended doses it is selective for MAO-B and no restrictions are required. Nevertheless, this report suggests that, rarely, interactions are still possible, and some consider that patients taking selegiline should try to avoid pseudoephedrine. The manufacturers of rasagiline recommend against concurrent use of nasal decongestants that are indirectly-acting sym- pathomimetics, such as ephedrine and pseudoephedrine, due to the risk of hypertensive crises.